National Securities Initiates Coverage on Anadys Pharmaceuticals (ANDS) with a Buy
ANDS Hot Sheet
Rating Summary:0 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
National Securities initiates coverage on Anadys Pharmaceuticals (Nasdaq: ANDS) with a Buy. Price target $5.
To see more analyst ratings on ANDS Click Here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
To see more analyst ratings on ANDS Click Here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
You May Also Be Interested In
- UPDATE: Auriga Starts Teva Pharma (TEVA) at Hold; Sidelined Until New CEO Is Convincing
- Wedbush Starts Erickson Air-Crane (EAC) at Outperform; Aircrane Sales Key to Upside
- Maxim's New Buy Rating, $14 Target on Acorn Energy (ACFN) Gives Investors Some Confidence
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
